TREATYNG

TREating Arrhythmogenic cardiomyopathy by TargetIng neuropeptide-Y signaliNG.

Financed by : Instituto de Salud Carlos III (ISCIII)

Program: ERDERA – Joint Transnational Call 2025 “Preclinical therapy studies for rare diseases using small molecules and biologicals – development and validation”

Project National Reference: AC25/00087

Role in the project: Partner

Duration: May 2026 to April 2029

 

Contact: José María Pérez Pomares

Implementation Centre: IBIMA Platform BIONAND 

Research group of IBIMA involved:  Cardiovascular Development and Disease Research Group

Abstract

Arrhythmogenic cardiomyopathy (ACM) is a rare and potentially life-threatening heart disease, often affecting young individuals and athletes. It is characterized by the progressive loss of cardiac muscle cells and their replacement by fibrous and fatty tissue, which can lead to impaired cardiac function and life-threatening arrhythmias. Currently, there are no effective therapies capable of preventing or stopping disease progression.

The TREATYNG project aims to develop new therapeutic strategies for ACM by investigating the role of neuro-cardiac communication, with a particular focus on Neuropeptide Y (NPY), a key co-transmitter of the sympathetic nervous system.

Recent research suggests that sympathetic neurons play an active role in the development and progression of ACM through their interactions with different cardiac cell types. TREATYNG will investigate whether targeting abnormal NPY signalling can prevent or slow disease progression and reduce the risk of cardiac complications.

Through an integrated approach combining in silico, molecular, cellular, in vivo and human cell-based studies, the project will explore the therapeutic potential of NPY-targeting agents, identify new therapeutic targets and develop prognostic biomarkers.

The international consortium brings together researchers with complementary expertise in cardiovascular biology, neuroscience, pharmacology and translational research, as well as patient organisations. This collaborative approach aims to accelerate the development of innovative therapeutic strategies and improve the prognosis and quality of life of people living with arrhythmogenic cardiomyopathy.

Partners

Related Links

          • ERDERA JTC 2025 selected projects – erdera.org

Aknowledgment

This project received funding from Instituto de Salud Carlos III (AC25/00087) under the umbrella of the Partnership European Rare Diseases Research Alliance (ERDERA) (GA N° 101156595 of the EU Horizon Europe Research and Innovation Programme).